Statins and the risk of interstitial lung disease: A cohort study

Thorax

Volumn 68, Issue 4, 2013, Pages 361-364

  Saad, Nathalie ^a   Camus, Philippe ^b   Suissa, Samy ^c   Ernst, Pierre ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b HÔPITAL DU BOCAGE   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; GENDER; HOSPITALIZATION; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRIORITY JOURNAL;

EID: 84875210831     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201823     Document Type: Article

References (20)

1. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93:914-21. (Pubitemid 47122038)
2. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. (Pubitemid 39140624)
3. Cheung BM, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-51. (Pubitemid 38582185)
4. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. (Pubitemid 30044262)
5. Federman AD, Adams AS, Ross-Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA 2001;286:1732-9. (Pubitemid 33010259)
6. Rashid S. Should cholesterol-lowering medications be available in Canada without a prescription? Can J Cardiol 2007;23:189-93. (Pubitemid 46744758)
7. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16. (Pubitemid 33044165)
8. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700. (Pubitemid 351810569)
9. Fernandez AB, Karas RH, Alsheikh-Ali AA, et al. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-30.
10. Dempsey OJ, Kerr KM, Remmen H, et al. How to investigate a patient with suspected interstitial lung disease. BMJ 2010;340:c2843.
11. Klingsberg RC, Mutsaers SE, Lasky JA. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology 2010;15:19-31.
12. Ponnuswamy A, Manikandan R, Sabetpour A, et al. Association between ischaemic heart disease and interstitial lung disease: a case-control study. Respir Med 2009;103:503-7.
13. Tzilas V, Koti A, Papandrinopoulou D, et al. Prognostic factors in idiopathic pulmonary fibrosis. Am J Med Sci 2009;338:481-5.
14. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991;151:1667-8.
15. De Groot RE, Willems LN, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Intern Med 1996;239:361-3. (Pubitemid 26106488)
16. Liebhaber MI, Wright RS, Gelberg HJ, et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999;115:886-9. (Pubitemid 29129979)
17. Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002;19:577-80. (Pubitemid 34256977)
18. Walker T, McCaffery J, Steinfort C. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust 2007;186:91-4. (Pubitemid 46178824)
19. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-72. (Pubitemid 24318021)
20. Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012;185:547-56.